China's State FDA Steps Up Transparency With First Annual Review Of Drug Approval Process, Outcome
This article was originally published in PharmAsia News
BEIJING - In a step toward lifting a longstanding veil on the drug review process in China, the State FDA has for the first time issued a public outline of the range and types of medicines approved by regulators last year
You may also be interested in...
In the coming years, SFDA will continue to drive drug approval efficiency to shorten drug review timelines.
3SBio Discontinues NuLeusin; Sinovac To Benefit From Government Vaccine Supply Plan: China Earnings Roundup (Part 3)
China's generic pharma companies suffered a slowdown in Q3, but biotech companies saw healthy growth.
China's State FDA increased drug approvals by more than 26% in 2010, with the boost largely due to an increase in generic drug approvals. The agency also cleared more clinical trials for drugs that treat diseases that have a large societal impact, according to SFDA's second annual report on the status of drug approvals